Solve this question paper. Use latest medical guidelines and evidences. Don't write long sentances. Give detail maximum answers in tables, flowchart and diagrams. Try to adress all possible aspect of questions including latest trials.
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
fertility preservation gynecological cancer
Searching PubMed
endometrial cancer fertility-sparing progestin treatment
Searching PubMed
endometrial cancer risk factors prevention
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
trachelectomy cervical cancer fertility outcomes
Searching PubMed
tamoxifen endometrial cancer risk
Searching PubMed
ovarian cancer fertility preservation ovarian transposition
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
chemoprevention endometrial cancer metformin aspirin
Reading File
Reading File
FERTILITY PRESERVATION IN GYNAECOLOGICAL CANCERS
Q1-3 & Q5: Fertility Preservation in Gynaecological Cancers
Overview Flowchart
YOUNG PATIENT WITH GYNAECOLOGICAL CANCER
|
┌─────────┴──────────┐
Desires future Does NOT desire
fertility? fertility → Standard Rx
|
┌────┴──────┐
Counselling by MDT
(Gynaec Oncologist + REI Specialist)
|
┌────┴────────────────────────────┐
| | |
CERVICAL CA UTERINE CA OVARIAN CA
| | |
(See below) (See below) (See below)
A. Cervical Cancer - Fertility Preservation
FIGO Stage Eligibility & Surgical Options
| Stage | Tumor Size | Procedure | Lymphadenectomy |
|---|---|---|---|
| IA1 (no LVSI) | <7 mm depth, <3 mm wide | Large LEEP / Cold knife cone | Not required |
| IA1 (LVSI+) or IA2 | <2 cm | Simple/Modified radical trachelectomy | Sentinel LN biopsy |
| IB1 | <2 cm, no LN mets | Radical vaginal/abdominal trachelectomy | Pelvic lymphadenectomy |
| IB2 (selected) | 2-4 cm | Neoadjuvant chemo → trachelectomy (experimental) | Pelvic LN dissection |
| >IB2 / LN positive | Any | NOT eligible for fertility-sparing | Standard chemoradiation |
Eligibility Criteria (FIGO/SGO)
- Age <45 years, strong desire for future fertility
- No evidence of infertility (unless addressable)
- Squamous or adenocarcinoma (no rare subtypes: small cell, NEEC)
- No LVSI (for IA1); limited LVSI acceptable for IA2/IB1
- No lymph node metastasis (confirm with imaging/sentinel LN biopsy)
- Tumor confined to cervix
- Upper 1 cm of endocervical canal free (intraoperative frozen section)
Radical Trachelectomy - Types
| Type | Approach | Notes |
|---|---|---|
| Radical Vaginal Trachelectomy (RVT) | Vaginal + laparoscopic LND | Gold standard (Dargent procedure); >2000 cases worldwide |
| Radical Abdominal Trachelectomy (RAT) | Open abdominal | Larger tumors; better parametrial excision |
| Laparoscopic / Robotic Trachelectomy | MIS | Meta-analysis (Lv Z, 2023, PMID 37838671): comparable oncologic outcomes to open; less blood loss |
| Simple Trachelectomy | Vaginal/abdominal | For stage IA1-IA2 low-risk; less morbidity |
Oncologic Outcomes (PMID 35241291 - Morice et al, Gynecol Oncol 2022)
- Recurrence rate: 2-5% for tumors <2 cm squamous, no LVSI
- Disease-free survival: comparable to radical hysterectomy in selected cases
- Recurrence risk rises sharply for tumors 2-4 cm
Reproductive Outcomes After Trachelectomy
| Outcome | Rate |
|---|---|
| Conception rate | >50% spontaneous |
| Require ART (IVF/IUI) | ~20% |
| Live birth rate | ~68% |
| Preterm delivery (<37 wks) | 20-30% |
| Cerclage placed at time of trachelectomy | Routine (permanent isthmic cerclage) |
- Source: Creasy & Resnik MFM; Berek & Novak's Gynecology
Ovarian Transposition (Oophoropexy) for Cervical Cancer
- Indicated when pelvic radiation likely (adjuvant or primary)
- Laparoscopic oophoropexy - move ovaries above pelvic brim to iliac crest level
- Meta-analysis (Laios A, 2022, PMID 35869476): ovarian function preserved in ~60-70%; ovarian failure rate significantly reduced vs non-transposed group
- Complications: partial ovarian failure due to scatter radiation, ovarian cysts
- Not effective if whole-abdominal or extended-field radiation planned
ASCO 2025 Guideline Update (PMID 40106739)
- Recommend discussing all fertility preservation options BEFORE treatment begins
- Embryo/oocyte cryopreservation is the standard (not experimental)
- Ovarian tissue cryopreservation is now accepted (no longer experimental per ASRM 2019)
- Ovarian suppression with GnRHa during chemotherapy: still investigational
B. Uterine (Endometrial) Cancer - Fertility-Sparing
ENDOMETRIAL CANCER + DESIRES FERTILITY
|
┌──────┴──────────┐
ELIGIBILITY CHECK
- Grade 1 endometrioid only
- No myometrial invasion (MRI)
- No extrauterine disease
- No synchronous ovarian malignancy
- Strongly desires fertility
|
┌──────┴──────────┐
IMAGING + BIOPSY STAGING
- MRI pelvis (myometrial invasion)
- Hysteroscopy with D&C
- CA125 + CBC + LFT
|
┌──────┴──────────┐
PROGESTIN THERAPY
(see table below)
|
Re-biopsy at 3-6 months
┌──────┴──────────┐
COMPLETE INCOMPLETE/PROGRESSION
RESPONSE → Hysterectomy + BSO + staging
|
Attempt conception (ART if needed)
|
Hysterectomy after childbearing
(or offer prophylactic surgery)
Progestin Regimens for Fertility-Sparing Treatment
| Drug | Dose | Route | Response Rate |
|---|---|---|---|
| Megestrol acetate | 160-320 mg/day | Oral | ~76% overall |
| Medroxyprogesterone acetate (MPA) | 400-600 mg/day | Oral | Similar to megestrol |
| Levonorgestrel IUS (Mirena) | 52 mg LNG | Intrauterine | ~80% (atypical hyperplasia), ~50-60% (EC) |
| Metformin + Progestin (combination) | 1500-2000 mg/day metformin | Oral add-on | Meta-analysis (Adamyan 2024, PMID 38503850): metformin significantly improves complete response rate (OR 2.17) |
Latest Trial Data (2024-2025)
- Cochrane Review 2025 (PMID 40626388) - Fernandez-Montoli et al: LNG-IUS + oral progestin combination may be superior to oral progestin alone; live birth rates ~30-40% after complete response
- Meta-analysis 2024 (PMID 39032722) - Suzuki et al, AJOG: Complete response rate Stage IA grade 1 EC = 76.3%; pregnancy rate after response = 41.4%; recurrence after complete response = 30-40%
- PMID 35526471 - De Rocco et al 2022: Live birth rate after fertility-sparing treatment = 40.5%
Selection Criteria for Endometrial Cancer Fertility-Sparing
| Include | Exclude |
|---|---|
| Grade 1 endometrioid | Grade 2/3 or non-endometrioid |
| No myometrial invasion on MRI | Any myometrial invasion |
| Stage IA (presumed) | Stage IB+ |
| Age <40 (ideally) | BRCA1/2 or Lynch syndrome (relative - counsel risk) |
| Desire to conceive | Not willing to follow-up |
| Normal CA-125 | Elevated CA-125 (suspect extrauterine) |
Follow-up Protocol
- Endometrial biopsy every 3 months during treatment
- Continue progestin for minimum 6 months
- If complete response at 6 months: attempt pregnancy (ART if needed)
- If no response at 6 months: discuss hysterectomy
- After achieving desired family size: definitive hysterectomy + BSO (mandatory counselling)
C. Ovarian Cancer - Fertility Preservation
Eligibility Criteria
- Young patient (<40 years)
- Stage IA, grade 1-2 epithelial ovarian cancer (EOC)
- OR borderline ovarian tumors (BOT) - any stage
- OR germ cell tumors - any stage
- OR sex cord-stromal tumors (stage IA)
Surgical Options by Tumor Type
| Tumor Type | Surgery | Notes |
|---|---|---|
| BOT (all stages) | USO + staging | Can preserve contralateral ovary + uterus even in stage II-III; low recurrence risk |
| EOC Stage IA G1-G2 | USO + comprehensive staging | Contralateral ovary + uterus preserved; close surveillance required |
| EOC Stage IA G3 / IB+ | Not recommended (relative contraindication) | Standard surgery preferred |
| Germ cell tumors | USO + staging + chemotherapy | Contralateral ovary preserved in virtually all; BEP chemotherapy; excellent prognosis |
| Sex cord-stromal (Stage IA) | USO | Risk of contralateral involvement is low |
| Hereditary (BRCA1/2) ovarian cancer | NOT eligible for fertility-sparing | Risk of bilateral disease too high |
- Berek & Novak's: Stage IA grade 1 EOC - 5-year survival >94% with USO alone (GOG RCT)
- Systematic review (Khattak 2022, PMID 35199164): ovarian tissue cryopreservation + transplant yields ~40% live birth rate
Ovarian Tissue Cryopreservation (OTC)
- Indicated when no time for oocyte stimulation (urgent chemo)
- Cortex strips harvested laparoscopically, slow-frozen/vitrified
- Reimplanted orthotopically (ovarian remnant) or heterotopically (forearm)
- Restored ovarian function in >95% of cases
- Live birth rate: 40% per reimplantation attempt (Khattak 2022, PMID 35199164)
- Caution: Risk of reintroducing malignancy with reimplantation (leukemia, ovarian cancer)
D. General Fertility Preservation Techniques
| Technique | Timing | Suitable For | Standard/Experimental |
|---|---|---|---|
| Embryo cryopreservation | Before treatment (2-4 weeks) | Partnered women | Standard |
| Oocyte cryopreservation | Before treatment (2-4 weeks) | Single women | Standard (ASRM 2013) |
| Ovarian tissue cryopreservation | Before treatment (1 day) | Pre-pubertal, urgent cases | Accepted (ASRM 2019) |
| GnRH agonist co-treatment | During chemo | Any female | Investigational |
| Ovarian transposition | Before radiation | Cervical/other pelvic Ca | Standard |
| Trachelectomy | Instead of hysterectomy | Cervical Ca stage IA-IB1 | Standard |
| Progestin therapy | Instead of surgery | Endometrial Ca G1 | Accepted with strict criteria |
Q EC1: 29-year-old with Infertility + Well-differentiated Endometrial Cancer
Evaluation Flowchart
29F - Primary Infertility + Well-differentiated Endometrial Cancer
|
┌───────────┴───────────┐
HISTORY EXAMINATION
- Duration infertility - BMI, signs of PCOS
- Menstrual history - Abdominal/pelvic exam
- Medications - Signs of hyperandrogenism
- Family Hx (Lynch?) - Uterine size/mobility
|
┌───────────┴───────────────────────────────┐
INVESTIGATIONS
| | | |
IMAGING BIOPSY BLOODS GENETIC
MRI pelvis Hysteroscopy CA-125, CEA MSI/MMR IHC
(depth of + D&C CBC, LFT Lynch testing
myometrial (confirm grade, HbA1c (MLH1, MSH2,
invasion) histotype) FSH/LH/AMH MSH6, PMS2)
Testosterone
Prolactin
MRI Staging - Key Parameters
| Parameter | Significance |
|---|---|
| Myometrial invasion depth | <50% (stage IA) - eligible for conservative |
| Cervical stromal involvement | Upstages to Stage II |
| Adnexal involvement | Extrauterine spread |
| Lymph node enlargement | Stage III disease |
| Endometrial thickness | Correlates with burden |
Management Algorithm
CONFIRMED G1 ENDOMETRIOID, NO MYOMETRIAL INVASION, NORMAL MRI
Criteria Met → FERTILITY-SPARING THERAPY
|
MULTIDISCIPLINARY COUNSELLING
(Gynaec Oncologist + REI Specialist + Counsellor)
|
PROGESTIN THERAPY
- LNG-IUS 52 mg (preferred - local high-dose delivery)
- ± Oral megestrol acetate 160 mg/day
- ± Metformin 1500 mg/day (if PCOS/insulin resistant)
|
SURVEILLANCE BIOPSY AT 3 MONTHS
|
┌────┴────────────┐
COMPLETE PARTIAL/NO
RESPONSE RESPONSE
| |
Biopsy at Increase dose or
6 months hysteroscopy + biopsy
|
Complete Still No Response
Response at 6m at 6 months → SURGERY
|
Attempt Conception
(ART if needed due to underlying infertility)
|
Pregnancy achieved
|
Post-delivery → HYSTERECTOMY + BSO
Patient Counselling Points
| Topic | Key Message |
|---|---|
| Standard treatment | Hysterectomy + BSO + staging - discuss this first |
| Conservative success | ~76% complete response rate; 30-40% recurrence after response |
| Pregnancy outcomes | ~40% live birth rate after complete response |
| Recurrence risk | 30-40% recurrence even after complete response |
| Definitive surgery | Mandatory after completing family |
| Lynch syndrome | Screen (immunohistochemistry for MMR) - 40-60% lifetime EC risk |
| PCOS connection | Address insulin resistance (metformin, weight loss) |
| Delay risk | If no response, delayed diagnosis worsens prognosis |
| Surveillance | Mandatory 3-monthly biopsies |
Q EC2: WHO Classification of Endometrial Hyperplasia + Risk Factors
WHO 2014/2020 Classification (Current)
| Category | Architecture | Cytology | Malignant Potential | Equivalent Old Term |
|---|---|---|---|---|
| Hyperplasia without atypia | Simple or complex | No atypia | 1-3% progression to cancer | Simple/Complex hyperplasia |
| Atypical hyperplasia / Endometrioid Intraepithelial Neoplasia (EIN) | Complex, crowded, back-to-back glands | Nuclear atypia present | 29% progression; 25-43% concurrent EC at hysterectomy | Atypical complex hyperplasia |
Note: The old WHO 1994 classification (Simple/Complex/Simple Atypical/Complex Atypical) has been replaced by the two-tier 2014 WHO system. The EIN concept (Endometrioid Intraepithelial Neoplasia) is now preferred by ISGP.
Progression to Cancer Rates (Kurman et al. classic study)
| Old Classification | New WHO | Progression |
|---|---|---|
| Simple (cystic, no atypia) | Hyperplasia without atypia | 1% |
| Complex (adenomatous, no atypia) | Hyperplasia without atypia | 3% |
| Simple atypical | Atypical hyperplasia/EIN | 8% |
| Complex atypical | Atypical hyperplasia/EIN | 29% |
Molecular Changes in Hyperplasia
| Gene/Pathway | Significance |
|---|---|
| PTEN | Mutated in >20% hyperplasias and 30-80% endometrioid carcinomas; earliest genetic event |
| PIK3CA | PI3K/AKT pathway activation |
| KRAS | Somatic mutations in hyperplasia + EC |
| MSI (Microsatellite Instability) | Lynch-associated; ~20% sporadic EC |
| CTNNB1 (β-catenin) | Endometrioid type |
| MLH1 hypermethylation | Sporadic MSI-H EC; not Lynch |
Risk Factors for Endometrial Cancer / Hyperplasia
| Risk Factor | Relative Risk | Mechanism |
|---|---|---|
| Obesity (21-50 lb overweight) | 3x | Peripheral conversion of androstenedione → estrone via aromatase |
| Obesity (>50 lb overweight) | 10x | Same + insulin resistance |
| Nulliparity | 2-3x | Prolonged estrogen exposure without progesterone |
| Late menopause (>52 yr) | 2.4x | Prolonged anovulatory/estrogen-dominant cycles |
| Unopposed estrogen therapy | 4-8x | Direct estrogenic stimulation |
| Tamoxifen therapy | 2-3x | Partial agonist effect on endometrium |
| Diabetes mellitus | 2.8x | Hyperinsulinemia stimulates IGF-1 |
| PCOS | 3-5x | Chronic anovulation + hyperandrogenism → excess estrone |
| Functioning ovarian tumor (granulosa cell) | High | Estrogen secretion |
| Lynch II syndrome (HNPCC) | 20x | MMR gene mutations (MLH1, MSH2, MSH6, PMS2) |
| Atypical hyperplasia | 8-29x | Direct precursor |
| Family history | 2-3x | Polygenic |
Protective factors: Combined OCP (50% RR reduction), multiparity, smoking (anti-estrogenic), physical activity, progestin therapy
- Source: Berek & Novak's Gynecology; Robbins & Cotran Pathologic Basis of Disease
Q EC3: Role of Chemoprevention in Endometrial and Ovarian Carcinoma
Endometrial Cancer Chemoprevention
| Agent | Mechanism | Evidence | Level |
|---|---|---|---|
| Combined OCP | Progestin opposes estrogen; inhibits proliferation | 50% RR reduction in endometrial Ca with ≥12 months use | Level I (meta-analysis) |
| Progestins (MPA/megestrol) | Direct antiproliferative on endometrium | Reverses hyperplasia; reduces progression to EC | Level II |
| LNG-IUS | Local progestin; endometrial atrophy | Highly effective for prevention in high-risk women (e.g., on tamoxifen) | Level II-III |
| Metformin | AMPK activation → inhibits mTOR → antiproliferative; reduces insulin/IGF-1 | PMID 38503850 (2024): Combined metformin + progestin significantly improves complete response vs progestin alone (OR 2.17) | Level I-II |
| Weight reduction | Reduces aromatization in adipose tissue | BMI reduction of 5 kg/m² reduces EC risk by ~50% | Population-level evidence |
| GLP-1 agonists (semaglutide etc.) | Weight loss + direct antiproliferative effects on endometrium (emerging) | Early observational data (2023-2025) | Level III - emerging |
| Aspirin / NSAIDs | COX-2 inhibition; reduces prostaglandin-mediated proliferation | Observational studies suggest 20-30% RR reduction; no RCT data for EC specifically | Level III |
| Bariatric surgery | Dramatic weight reduction; corrects hyperinsulinemia | EC risk dramatically reduced post-bariatric surgery | Level II |
Chemoprevention in Specific High-Risk Groups
| Group | Strategy |
|---|---|
| Obese women with PCOS | Metformin + weight loss program + cyclic progestins |
| Lynch syndrome | Prophylactic hysterectomy + BSO post-childbearing; annual surveillance from age 35-40 |
| Tamoxifen users | LNG-IUS; annual TVU if symptomatic |
| Atypical hyperplasia (no fertility desire) | Hysterectomy preferred; progestins if surgery declined |
| Atypical hyperplasia (fertility desired) | LNG-IUS + oral progestin ± metformin |
Ovarian Cancer Chemoprevention
| Agent | Mechanism | Evidence | RR Reduction |
|---|---|---|---|
| Combined Oral Contraceptive Pill | Suppresses ovulation; reduces number of ovulatory events | Most robust data; >5 years use reduces risk ~50% | 30-60% |
| Tubal ligation / salpingectomy | Removes putative route of malignant cell entry from endometrium/environment | Salpingectomy at time of other surgery reduces high-grade serous ovarian Ca risk | ~40-60% |
| BRCA carriers: Prophylactic BSO | Removes at-risk tissue | BRCA1: risk-reduction BSO by age 35-40; BRCA2: by age 40-45 | >90% |
| Oral OCP in BRCA carriers | As above | Reduces ovarian Ca risk even in BRCA1/2 carriers | 20-40% (BRCA1 disputed) |
| Aspirin | Anti-inflammatory/anti-proliferative | Observational studies; 20% RR reduction | Level III |
| GnRH analogs | Ovarian suppression | No clear preventive evidence; not recommended | N/A |
| Breastfeeding / Multiparity | Reduces ovulatory cycles | Each pregnancy reduces risk ~10-15% | Protective |
BRCA Chemoprevention Algorithm: BRCA1: Screen from age 25 → discuss prophylactic BSO by age 35-40 → if surgery deferred, OCP use BRCA2: Screen from age 25-30 → prophylactic BSO by age 40-45
Q EC4: Tamoxifen and Endometrial Pathologies
Mechanism of Tamoxifen on Endometrium
TAMOXIFEN
|
Selective Estrogen Receptor Modulator (SERM)
|
┌─────────────────┬─────────────────┐
BREAST BONE UTERUS/ENDOMETRIUM
Antagonist Agonist *** AGONIST ***
(therapeutic (protective) (pathologic)
in breast Ca) |
Estrogen-like effects
on endometrium
Endometrial Pathologies Associated with Tamoxifen
| Pathology | Incidence | Risk vs No Tamoxifen | Notes |
|---|---|---|---|
| Endometrial polyps | 8-36% | 2-3x increased | Most common finding; usually benign |
| Endometrial hyperplasia | 2-4x baseline | 2-4x | Precancerous; needs surveillance |
| Endometrial carcinoma | RR 2-3x | 2-3x | Usually well-differentiated Type I; PMID 36916539 (2023): dose-response relationship confirmed |
| Uterine sarcoma | Rare but increased | 3x | Especially malignant mixed Mullerian tumor |
| Endometrial atrophy with cystic change | Common | Benign | Sub-epithelial stromal fibrosis + gland cystic change |
Meta-analysis Evidence (PMID 36916539, Cancer Reports 2023)
- Duration >5 years: significantly higher endometrial cancer risk vs <5 years
- Dose-response confirmed: higher cumulative dose = higher risk
- Risk persists for years after stopping tamoxifen
- Postmenopausal women at higher risk than premenopausal
Surveillance Recommendations for Tamoxifen Users
| Society | Recommendation |
|---|---|
| ACOG / SGO | No routine screening with TVU or endometrial biopsy in asymptomatic women |
| ASCO | Prompt investigation of any abnormal uterine bleeding in tamoxifen users |
| ESGO | Annual pelvic examination; TVU only if symptomatic |
| Berek & Novak's (textbook) | "Women taking tamoxifen receive no benefit from routine screening with TVU or endometrial biopsy" |
Key principle: Tamoxifen use should not trigger routine screening, but ANY abnormal uterine bleeding must be investigated immediately with endometrial biopsy.
Management Options
| Situation | Management |
|---|---|
| Asymptomatic on tamoxifen | Routine pelvic exam; no biopsy unless symptomatic |
| Symptomatic (AUB) on tamoxifen | TVU → if ET >4 mm (postmenopausal): endometrial biopsy |
| Endometrial polyp on tamoxifen | Hysteroscopic polypectomy |
| Hyperplasia without atypia | LNG-IUS; consider switching to aromatase inhibitor |
| Atypical hyperplasia | Hysterectomy (preferred) OR progestin therapy + stop tamoxifen |
| Endometrial cancer | Hysterectomy + staging; consider switching to aromatase inhibitor |
| Switching from tamoxifen | Aromatase inhibitor (postmenopausal) reduces endometrial risk while maintaining breast protection |
Q EC5: Risk Factors of Endometrial Cancer and Prevention
Risk Factor Table (with Relative Risk)
| Category | Risk Factor | Relative Risk |
|---|---|---|
| Hormonal | Unopposed estrogen therapy | 4-8x |
| Tamoxifen use | 2-3x | |
| Estrogen-secreting tumor (granulosa cell) | High | |
| Metabolic | Obesity (>50 lb overweight) | 10x |
| Diabetes mellitus | 2.8x | |
| Metabolic syndrome / PCOS | 3-5x | |
| Insulin resistance | 2-4x | |
| Reproductive | Nulliparity | 2-3x |
| Infertility / anovulation | 2-3x | |
| Late menopause (>52 yr) | 2.4x | |
| Early menarche | 1.5-2x | |
| Genetic | Lynch syndrome (HNPCC) | 20x (40-60% lifetime risk) |
| Family history of EC | 2-3x | |
| PTEN mutation (Cowden syndrome) | High | |
| Precursor | Atypical hyperplasia / EIN | 8-29x |
| Complex hyperplasia without atypia | 3x | |
| Iatrogenic | Pelvic radiation (prior) | 8x |
Prevention Strategies
Primary Prevention
| Strategy | Method | Evidence |
|---|---|---|
| Weight management | BMI <25; exercise ≥150 min/week | Each 5 kg/m² BMI increase → 50% risk increase; weight loss reduces risk |
| Combined OCP | ≥12 months use | 50% risk reduction; protective effect lasts >15 years after stopping |
| Physical activity | Regular aerobic exercise | Reduces endogenous estrogen, insulin resistance |
| Treat anovulation | Cyclic progestins in PCOS | Prevents unopposed estrogen buildup |
| Progestin opposition | Use progestin with HRT | Cancels estrogenic risk of HRT |
| LNG-IUS | High-risk women (e.g., Lynch) | Endometrial atrophy |
| Bariatric surgery | Morbid obesity | Dramatic risk reduction |
| Metformin | Insulin-resistant/PCOS women | Emerging chemopreventive evidence |
Secondary Prevention (High-Risk Groups)
| Group | Surveillance | Preventive Surgery |
|---|---|---|
| Lynch syndrome | Annual TVU + endometrial biopsy from age 35-40 | Prophylactic hysterectomy + BSO after childbearing |
| Atypical hyperplasia | 3-6 monthly biopsy | Hysterectomy (if no fertility desire) |
| Tamoxifen users | Pelvic exam; biopsy only if symptomatic | Switch to aromatase inhibitor if possible |
| Obese PCOS | Annual/biennial TVU; biopsy if AUB | Metformin + lifestyle modification |
| Cowden syndrome (PTEN) | Annual screening from age 30-35 | Prophylactic hysterectomy after childbearing |
Prevention Algorithm
RISK ASSESSMENT AT EVERY GYNECOLOGICAL VISIT
|
┌────┴────────────────┐
HIGH RISK LOW RISK
(Lynch, PCOS, obese, Reassure + lifestyle counselling
atypical hyperplasia,
tamoxifen, PTEN)
|
├─── Modify Reversible Factors
│ (Weight loss, OCP, cyclic progestins, metformin)
|
├─── Surveillance (TVU + Biopsy per guideline)
|
└─── Prophylactic Surgery (post-childbearing)
- Hysterectomy + BSO for Lynch, PTEN
Key Latest Evidence Summary
| PMID | Year | Study | Key Finding |
|---|---|---|---|
| 40626388 | 2025 | Cochrane Review - Fernandez-Montoli | LNG-IUS + oral progestin superior to oral alone for fertility-sparing in AEH/EC |
| 39032722 | 2024 | Suzuki et al, AJOG | Stage IA G1 EC fertility-sparing: 76.3% complete response; 41.4% pregnancy rate |
| 38503850 | 2024 | Adamyan et al | Metformin + progestin: OR 2.17 for complete response vs progestin alone |
| 40106739 | 2025 | ASCO Guideline Update | OTC now standard; GnRHa still investigational; all options pre-treatment |
| 35241291 | 2022 | Morice et al | Trachelectomy recurrence <5% for tumors <2 cm squamous no LVSI |
| 35869476 | 2022 | Laios et al | Ovarian transposition: 60-70% ovarian function preservation |
| 36916539 | 2023 | Ghanavati et al | Tamoxifen: dose-response for endometrial cancer risk confirmed |
| 35199164 | 2022 | Khattak et al | OTC + transplant: 40% live birth rate |
Sources: Berek & Novak's Gynecology; Robbins & Cotran Pathologic Basis of Disease; Creasy & Resnik's Maternal-Fetal Medicine; Goldman-Cecil Medicine; ASCO 2025 Guideline (PMID 40106739); Multiple PubMed systematic reviews cited above.
This is a shared conversation. Sign in to Orris to start your own chat.